Muna Therapeutics vs Microbiotica
Side-by-side comparison of AI visibility scores, market position, and capabilities
Muna Therapeutics raised $75M in 2024 targeting microglial biology in Alzheimer's disease, using iPSC-derived microglia models to identify novel drug targets that modulate brain immune function.
About
Muna Therapeutics focuses on microglial biology — the specialized immune cells of the brain — as the key to developing disease-modifying Alzheimer's therapies beyond amyloid targeting. The company uses induced pluripotent stem cell (iPSC)-derived microglia as disease models to identify and validate novel drug targets implicated by Alzheimer's genetics (TREM2, PLCG2, BIN1, APOE). This platform enables the company to study microglial dysfunction at scale and run drug screens against human-relevant cellular models.
Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains to disease, enabling live biotherapeutic products for cancer immunotherapy and IBD.
About
Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bacterial strains responsible. The company's Reference Microbiome database — built from thousands of patient samples — is the world's most comprehensive catalog of gut bacteria linked to disease outcomes, providing a systematic foundation for microbiome drug discovery.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.